Buprenorphine And Naloxone Tablet
Product Images NDC 0228-3154

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Buprenorphine And Naloxone (NDC 0228-3154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Round Tablets (Image 1)

Buprenorphine and Naloxone sublingual tablets from Actavis Pharma, Inc. The label shows tablets in two colors, light yellow and white, each imprinted with 'ACT' and respective dosage strengths: 8 mg/2 mg and 2 mg/0.5 mg. The package indicates a count of 7 tablets per blister card.*

FDA Label Image

The Following Chemical Structure Of Buprenorphine HCl, Usp Has The Molecular Formula C29h41no4 • HCl And The Molecular Weight Is 504.10. It Is A White Or Off-white Crystalline Powder, Sparingly Soluble In Water, Freely Soluble In Methanol, Soluble In Alcohol, And Practically Insoluble In Cyclohexane. (Image 2)

Chemical structure of Buprenorphine Hydrochloride, showing its molecular formula C29H41NO4 with an HCl component and a molecular weight of 504.10.*

FDA Label Image

The Following Chemical Structure Of Naloxone Hydrochloride Dihydrate, Usp Has The Molecular Formula C19h21no4 • HCl • 2h2o And The Molecular Weight Is 399.87. It Is A White To Slightly Off-white Powder And Is Freely Soluble In Water, Soluble In Alcohol, And Practically Insoluble In Toluene And Ether. (Image 3)

Chemical structure of Buprenorphine hydrochloride dihydrate, showing its molecular framework with rings, hydroxyl, and nitrogen groups, along with its molecular formula C19H21NO4 and molecular weight 399.87.*

FDA Label Image

Round Tablet (Image 4)

Packaging label of Buprenorphine and Naloxone sublingual tablets by Actavis Pharma, Inc. The visible bottle label shows the proprietary and generic names, dosage form as tablets, and the labeler information. Specific strength or count details are not visible in the image.*

FDA Label Image

Round Tablet (Image 5)

A rectangular blister card containing six sublingual tablets of Buprenorphine and Naloxone. The foil backing is white with black printed text displaying the dosage strengths: 2 mg of Buprenorphine and 0.5 mg of Naloxone. The labeler Actavis Pharma, Inc. is identified. The tablets are organized in two rows of three.*

FDA Label Image

2 (Image 6)

An illustration showing a person administering a sublingual tablet inside the mouth. The tablet is placed under the tongue, demonstrating the proper sublingual route of administration for buprenorphine and naloxone tablets.*

FDA Label Image

1 (Image 7)

Label for Buprenorphine and Naloxone Sublingual Tablets, USP, strength 2 mg/0.5 mg. The label specifies the medication is for sublingual use, with a 30 tablet count. It includes warnings about accidental ingestion by children, storage conditions, and dispensing instructions. Manufactured by Teva Pharmaceuticals.*

FDA Label Image

1 (Image 8)

Label for Buprenorphine and Naloxone Sublingual Tablets, USP 8 mg/2 mg, produced by Actavis Pharma, Inc. The label shows a container with 30 tablets. It states the active ingredients include 8 mg of buprenorphine base and 2 mg of naloxone base per tablet, and includes storage instructions, a barcode, and warnings to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.